Castrate resistant prostate cancer (CRPC) refers to prostate cancer that continues to grow and spread even after the medical or surgical treatment to lower testosterone. It becomes resistant to these standard hormonal treatments that aimed to deprive prostate cancer cells of the male sex hormone testosterone that fuels their growth. Currently, chemotherapy is the standard treatment for CRPC, however improvements in diagnostics have led to earlier detection enabling new drug therapies which ... Read more
